KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis
Canada - TSX:GUD - CA4990531069 - Common Stock
6.15 CAD
-0.09 (-1.44%)
Taking everything into account, GUD scores 5 out of 10 in our fundamental rating. GUD was compared to 31 industry peers in the Pharmaceuticals industry. While GUD seems to be doing ok healthwise, there are quite some concerns on its profitability. GUD is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
GUD had negative earnings in the past year.
In the past year GUD had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: GUD reported negative net income in multiple years.
Of the past 5 years GUD 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.04%, GUD is in the better half of the industry, outperforming 61.29% of the companies in the same industry.
With a decent Return On Equity value of 0.05%, GUD is doing good in the industry, outperforming 64.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.04% | ||
| ROE | 0.05% | ||
| ROIC | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 0.10%, GUD is in the better half of the industry, outperforming 61.29% of the companies in the same industry.
In the last couple of years the Profit Margin of GUD has declined.
The Gross Margin of GUD (42.92%) is comparable to the rest of the industry.
GUD's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 0.1% | ||
| GM | 42.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GUD has been reduced compared to 1 year ago.
The number of shares outstanding for GUD has been reduced compared to 5 years ago.
GUD has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.15 indicates that GUD is not a great score, but indicates only limited risk for bankruptcy at the moment.
GUD has a better Altman-Z score (2.15) than 87.10% of its industry peers.
GUD has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.11, GUD is in the better half of the industry, outperforming 64.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.15 |
ROIC/WACCN/A
WACC8.42%
2.3 Liquidity
A Current Ratio of 2.47 indicates that GUD has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.47, GUD is doing good in the industry, outperforming 64.52% of the companies in the same industry.
GUD has a Quick Ratio of 1.50. This is a normal value and indicates that GUD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.50, GUD is in the better half of the industry, outperforming 64.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.47 | ||
| Quick Ratio | 1.5 |
3. Growth
3.1 Past
GUD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 100.00%, which is quite impressive.
GUD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.46% yearly.
The Revenue has grown by 13.82% in the past year. This is quite good.
GUD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 50.87% yearly.
EPS 1Y (TTM)100%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-550%
Revenue 1Y (TTM)13.82%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%12.33%
3.2 Future
The Earnings Per Share is expected to grow by 54.05% on average over the next years. This is a very strong growth
GUD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.10% yearly.
EPS Next Y-330.28%
EPS Next 2Y10.09%
EPS Next 3Y50.87%
EPS Next 5Y54.05%
Revenue Next Year14.81%
Revenue Next 2Y12.31%
Revenue Next 3Y8.59%
Revenue Next 5Y10.1%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Forward Earnings ratio of 101.49, GUD can be considered very expensive at the moment.
GUD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. GUD is cheaper than 67.74% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.57, GUD is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 101.49 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GUD is valued a bit cheaper than 61.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 13.73 |
4.3 Compensation for Growth
A more expensive valuation may be justified as GUD's earnings are expected to grow with 50.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.09%
EPS Next 3Y50.87%
5. Dividend
5.1 Amount
No dividends for GUD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:GUD (11/13/2025, 7:00:00 PM)
6.15
-0.09 (-1.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.23%
Inst Owner ChangeN/A
Ins Owners1.86%
Ins Owner ChangeN/A
Market Cap613.03M
Revenue(TTM)384.56M
Net Income(TTM)383.00K
Analysts78.18
Price Target7.96 (29.43%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-224.57%
Min EPS beat(2)-815.07%
Max EPS beat(2)365.93%
EPS beat(4)2
Avg EPS beat(4)-21.94%
Min EPS beat(4)-815.07%
Max EPS beat(4)461.4%
EPS beat(8)3
Avg EPS beat(8)-230%
EPS beat(12)6
Avg EPS beat(12)-123.05%
EPS beat(16)7
Avg EPS beat(16)-384.28%
Revenue beat(2)2
Avg Revenue beat(2)5.97%
Min Revenue beat(2)0.88%
Max Revenue beat(2)11.06%
Revenue beat(4)4
Avg Revenue beat(4)5.89%
Min Revenue beat(4)0.88%
Max Revenue beat(4)11.06%
Revenue beat(8)7
Avg Revenue beat(8)5%
Revenue beat(12)11
Avg Revenue beat(12)8.91%
Revenue beat(16)14
Avg Revenue beat(16)9.42%
PT rev (1m)0%
PT rev (3m)3.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-110.42%
EPS NY rev (1m)0%
EPS NY rev (3m)-302.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 101.49 | ||
| P/S | 1.59 | ||
| P/FCF | N/A | ||
| P/OCF | 20.16 | ||
| P/B | 0.8 | ||
| P/tB | 2.13 | ||
| EV/EBITDA | 13.73 |
EPS(TTM)0
EYN/A
EPS(NY)0.06
Fwd EY0.99%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.31
OCFY4.96%
SpS3.86
BVpS7.66
TBVpS2.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.04% | ||
| ROE | 0.05% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 0.1% | ||
| GM | 42.92% | ||
| FCFM | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score6
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.96 | ||
| Cap/Depr | 62.43% | ||
| Cap/Sales | 8.29% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 72.19% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.47 | ||
| Quick Ratio | 1.5 | ||
| Altman-Z | 2.15 |
F-Score6
WACC8.42%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-550%
EPS Next Y-330.28%
EPS Next 2Y10.09%
EPS Next 3Y50.87%
EPS Next 5Y54.05%
Revenue 1Y (TTM)13.82%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%12.33%
Revenue Next Year14.81%
Revenue Next 2Y12.31%
Revenue Next 3Y8.59%
Revenue Next 5Y10.1%
EBIT growth 1Y-652.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year397.68%
EBIT Next 3Y80.27%
EBIT Next 5Y54.06%
FCF growth 1Y-140.33%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y60.79%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
Can you provide the ChartMill fundamental rating for KNIGHT THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to GUD.CA.
Can you provide the valuation status for KNIGHT THERAPEUTICS INC?
ChartMill assigns a valuation rating of 2 / 10 to KNIGHT THERAPEUTICS INC (GUD.CA). This can be considered as Overvalued.
What is the profitability of GUD stock?
KNIGHT THERAPEUTICS INC (GUD.CA) has a profitability rating of 3 / 10.
What is the financial health of KNIGHT THERAPEUTICS INC (GUD.CA) stock?
The financial health rating of KNIGHT THERAPEUTICS INC (GUD.CA) is 6 / 10.
Can you provide the expected EPS growth for GUD stock?
The Earnings per Share (EPS) of KNIGHT THERAPEUTICS INC (GUD.CA) is expected to decline by -330.28% in the next year.